Long-term denosumab therapy safe for patients with breast, prostate cancer
the ONA take:
No new safety signals were identified for long-term denosumab therapy in patients with metastatic breast or prostate cancer and bone metastases, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
In the initial blinded phase 3 studies, patients with metastatic breast or prostate cancer received subcutaenous denosumab 120 mg every 4 weeks or intravenous zolendronic acid 4 mg every 4 weeks.
Denosumab was found to be superior in efficacy to zoledronic acid, and therefore patients could opt to participate in an open-label extension to receive long-term denosumab for up to an additional 2 years.
Researchers analyzed the data from the open-label extension to evaluate the safety results of extended denosumab therapy.
Results showed no new safety signals among patients who continued denosumab or among patients who switched from zoledronic acid to denosumab. Osteonecrosis of the jaw rates increased with increasing exposure to denosumab, while hypocalcemia rates were similar between the blinded treatment and open-label extension phases.
No new safety signals were identified for long-term denosumab therapy in patients with metastatic breast or prostate cancer and bone metastases.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|